Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Divarasib plus Pembrolizumab versus Pembrolizumab with pemetrexed and platinum in previously untreated KRAS G12C-mutant non-squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Divarasib
• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer | Phase 3 | Status: RECRUITING